Krupa Patel
Family · Fort Worth, TXNPI 1457011512
Payments from drug & device makers
Across 159 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$534
- AstraZeneca$443
- GSK$379
- Boehringer Ingelheim$327
- Insmed, Inc.$260
- Supernus Pharmaceuticals, Inc.$135
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,222100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 18 | $534 |
| AstraZeneca | 20 | $443 |
| GSK | 24 | $379 |
| Boehringer Ingelheim | 14 | $327 |
| Insmed, Inc. | 13 | $260 |
| Supernus Pharmaceuticals, Inc. | 6 | $135 |
| Amgen | 7 | $129 |
| Novo Nordisk | 8 | $125 |
| AbbVie | 10 | $117 |
| Sanofi | 4 | $108 |
| Actelion Pharmaceuticals US, Inc. | 3 | $78 |
| Harmony Biosciences LLC | 3 | $77 |
| Mylan Specialty L.p. | 4 | $64 |
| Bayer | 3 | $48 |
| Grifols USA, LLC | 2 | $46 |
| Pfizer | 3 | $45 |
| Paratek Pharmaceuticals, Inc. | 2 | $42 |
| Amarin Pharma, Inc. | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Lilly USA, LLC | 2 | $27 |
| United Therapeutics Corporation | 1 | $26 |
| Inogen, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Exact Sciences | 1 | $20 |
| Novartis | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Medtronic | 1 | $13 |
| Seqirus USA Inc | 1 | $13 |
How this compares
$3,230 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 222 | $168,584 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 91 | $73,265 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 58 | $32,261 |
| Spiriva RespimatTiotropium Bromide | 39 | $28,805 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $24,136 |
| SymbicortBudesonide/Formoterol Fumarate | 86 | $22,688 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $19,469 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $9,923 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 78 | $9,752 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 392 | $8,745 |
| Arnuity ElliptaFluticasone Furoate | 27 | $6,250 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $5,337 |
| BreynaBudesonide/Formoterol Fumarate | 14 | $4,893 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $3,944 |
| Azelastine Hcl | 80 | $2,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $379 | $223,776351 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $443 | $95,952177 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $327 | $70,989111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.
Other family in Fort Worth
- Laura MoeFort Worth$158K
- Julie TaylorFort Worth$63K
- Ryan BourgeoisFort Worth$37K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.